New drug combo tested to shrink breast tumors before surgery
NCT ID NCT07246317
Summary
This study is testing which of two drug combinations works better to shrink tumors before surgery in people with HER2-positive breast cancer. About 188 participants will receive either the standard three-drug combination plus a new drug called QL1706, or the standard combination plus carboplatin. The goal is to see which approach leads to more patients having no detectable cancer left at surgery and which is safer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Jiaxing University
Jiaxing, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Nanyang Central Hospital
Nanyang, Henan, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital, Sun Yat-sen University (FAH-SYSU)
Guangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The West China Second University Hospital of Sichuan University (WCSUH- SCU)
Chengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.